Calcium phosphate cement delivering zoledronate decreases bone turnover rate and restores bone architecture in ovariectomized rats

Biomedical Materials

Volumn 7, Issue 3, 2012, Pages

  Wu, Chang Chin ^a,b   Wang, Chen Chie ^a,c   Lu, Dai Hua ^a   Hsu, Li Ho ^b   Yang, Kai Chiang ^d   Lin, Feng Huei ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b EN CHU KONG HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DISEASES; MICROGRAVITY PROCESSING; PHOSPHATASES; RATS; RESTORATION; TOXICITY;

ALKALINE PHOSPHATASE; BLOOD SAMPLES; BONE ARCHITECTURE; BONE ASH; BONE DEFECT; BONE FORMATION MARKERS; BONE GRAFT SUBSTITUTES; BONE MINERAL CONTENT; BONE RESORPTION MARKERS; BONE TURNOVER; BONE-FILLERS; CALCIUM PHOSPHATE CEMENT; CANCELLOUS BONE; CLINICAL SIGNS; CONCOMITANT DECREASE; MICRO CT; MICRO-CT SCANNING; OSTEOCALCIN; OSTEOPONTIN; POSTMENOPAUSAL WOMEN; TYPE I COLLAGEN;

BONE;

ALKALINE PHOSPHATASE; BONE CEMENT; CALCIUM PHOSPHATE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; OSTEOPONTIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE GRAFT; BONE MINERAL; BONE STRUCTURE; BONE TURNOVER; CANCELLOUS BONE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; FEMUR; HEMATOLOGY; HISTOLOGY; METAPHYSIS; NONHUMAN; OMENTUM; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; RAT; ANIMAL; HUMAN; PATHOLOGY; TREATMENT OUTCOME; WISTAR RAT;

RATTUS;

ANIMALS; BONE CEMENTS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM PHOSPHATES; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84858976853     PISSN: 17486041     EISSN: 1748605X     Source Type: Journal    
DOI: 10.1088/1748-6041/7/3/035009     Document Type: Article

References (53)

1. Rodríguez-Lorenzo L M and Ferreira J M F 2004 Development of porous ceramic bodies for applications in tissue engineering and drug delivery systems Mater. Res. Bull. 39 83-91
2. Verron E, Khairoun I, Guicheux J and Bouler J M 2010 Calcium phosphate biomaterials as bone drug delivery systems: a review Drug Discovery Today 15 547-52
3. Beardmore A A, Brooks D E, Wenke J C and Thomas D B 2005 Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute J. Bone Joint Surg. Am. 87 107-12 (Pubitemid 40094145)
4. Mouriño V and Boccaccini A R 2010 Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds J. R. Soc. Interface 7 209-27
5. Thomas D B, Brooks D E, Bice T G, DeJong E S, Lonergan K T and Wenke J C 2005 Tobramycin-impregnated calcium sulfate prevents infection in contaminated wounds Clin. Orthop. Relat. Res. 441 366-71 (Pubitemid 44384246)
6. Galjour C, Dzugan S, Graves M, Benghuzzi H, Russell G, Tucci M and Tsao A 2005 Stimulation of fracture healing by continuous delivery of demineralized bone matrix proteins and tobramycin Biomed. Sci. Instrum. 41 122-7
7. Sasaki T, Ishibashi Y, Katano H, Nagumo A and Toh S 2005 In vitro elution of vancomycin from calcium phosphate cement J. Arthroplasty 20 1055-9 (Pubitemid 41820994)
8. Eguchi Y, Wakitani S, Naka Y, Nakamura H and Takaoka K 2011 An injectable composite material containing bone morphogenetic protein-2 shortens the period of distraction osteogenesis in vivo J. Orthop. Res. 29 452-6
9. Bouxsein M L et al 2006 Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT J. Bone Miner. Res. 21 1475-82 (Pubitemid 44300054)
10. Russell R G, Espina B and Hulley P 2006 Bone biology and the pathogenesis of osteoporosis Curr. Opin. Rheumatol. 18 3-10
11. Takeda S 2008 Central control of bone remodeling J. Neuroendocrinol. 20 802-7
12. Hao Y J, Zhang G, Wang Y S, Qin L, Hung W Y, Leung K and Pei F X 2007 Changes of microstructure and mineralized tissue in the middle and late phase of osteoporotic fracture healing in rats Bone 41 631-8 (Pubitemid 47385430)
13. Namkung-Matthai H, Appleyard R, Jansen J, Hao Lin J, Maastricht S, Swain M, Mason RS, Murrell G A, Diwan A D and Diamond T 2001 Osteoporosis influences the early period of fracture healing in a rat osteoporotic model Bone 28 80-6 (Pubitemid 32112065)
14. Giannoudis P V and Schneider E 2006 Principles of fixation of osteoporotic fractures J. Bone Joint Surg. Br. 88 1272-8 (Pubitemid 44636844)
15. Stadelmann V A, Gauthier O, Terrier A, Bouler J M and Pioletti D P 2008 Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study Eur. Cell Mater. 16 10-6
16. Peter B et al 2006 Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats J. Biomed. Mater. Res. A 76 133-43 (Pubitemid 43075691)
17. Graham R and Russell G 2006 Bisphosphonates Ann. New York Acad. Sci. 1068 367-401
18. Boivin G and Meunier P J 2002 Effects of bisphosphonates on matrix mineralization J. Musculoskelet. Neuronal. Interact. 2 538-43 (Pubitemid 36157597)
19. Chapurlat R D and Delmas P D 2006 Drug insight: bisphosphonates for postmenopausal osteoporosis Nat. Clin. Pract. Endocrinol. Metab. 2 211-9
20. Chapurlat R D 2005 Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis Treat. Endocrinol. 4 115-25 (Pubitemid 40516578)
21. McLaren A C 2004 Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections Clin. Orthop. Relat. Res. 427 101-6 (Pubitemid 39362838)
22. Wagoner Johnson A J and Herschler B A 2011 A review of the mechanical behavior of CaP and CaP/polymer composites for applications in bone replacement and repair Acta Biomater. 7 16-30
23. Low K L, Tan S H, Zein S H, Roether J A, Mouriño V and Boccaccini A R 2010 Calcium phosphate-based composites as injectable bone substitute materials J. Biomed. Mater. Res. Appl. Biomater. B 94 273-86
24. Peter B, Pioletti D P, Laïb S, Bujoli B, Pilet P, Janvier P, Guicheux J, Zambelli P Y, Bouler J M and Gauthier O 2005 Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration Bone 36 52-60 (Pubitemid 40128274)
25. Woodis C B 2008 Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis Ann. Pharmacother. 42 1085-9
26. Reid D M et al 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 373 1253-63
27. Black D M et al Cummings S R and HORIZON Pivotal Fracture Trial 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N. Engl. J. Med. 356 1809-22
28. Lyles K W et al HORIZON Recurrent Fracture Trial 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N. Engl. J. Med. 357 1799-809
29. Health Sciences Authority 2010 Zoledronic acid (Aclasta R®) and rare reports of renal impairment Adverse Drug Reaction News Bulletin 2010 December vol 12 no 2 http://www.hsa.gov.sg/publish/etc/medialib/hsa-library/health- products-regulation/safety-information/adr-news-bulletin.Par.69326.File.tmp/ ADR-News-Aug2010-Vol12-No2.pdf
30. Kharode Y P, Sharp M C and Bodine P V 2008 Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery Methods Mol. Biol. 455 111-24
31. Higuchi T, Tanaka K and Mizunuma H 2003 Estrogen replacement therapy for osteoporosis in postmenopausal women Clin. Calcium 13 1450-6
32. Yang K C, Wu C C, Sumi S, Kuo T F, Lin S C and Lin F H 2010 Intramedullary cavity as an implant site for bioartificial pancreas: an in vivo study on diabetic canine Transplantation 90 604-11
33. Yang K C, Wang C C, Wu C C, Huang T Y, Chang H C, Chang H K and Lin F H 2010 Acute and subacute oral toxicity test of sintered dicalcium pyrophosphate on ovariectomized rats for osteoporosis treatment Biomed. Eng. Appl. Basis. Comm. 22 169-76
34. Ammann P, Brennan T C, Mekraldi S, Aubert M L and Rizzoli R 2010 Administration of growth hormone in selectively protein-deprived rats decreases BMD and bone strength Bone 46 1574-81
35. Khapra A P and Rose S 2006 Drug injury in the upper gastrointestinal tract: effects of alendronate Gastrointest. Endosc. Clin. N. Am. 16 99-110
36. Reid I R, Bolland M J and Grey A B 2007 Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41 318-20 (Pubitemid 47199147)
37. Milewicz A, Tworowska U and Demissie M 2001 Menopausal obesity-myth or fact? Climacteric 4 273-83
38. Ogawa K, Hori M, Takao R and Sakurada T 2005 Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats J. Bone Miner. Metab. 23 351-8 (Pubitemid 41223797)
39. Yang K C, Yen K C, Huang J Y, Wu C C and Lin F H 2011 Sintered dicalcium pyrophosphate decreases bone turnover rate in osteoporotic rat: a study on serum biochemical bone turnover markers Biomed. Aging Pathol. 1 46-51
40. Markus J S 2005 Biochemical markers of bone turnover: part I. Biochemistry and variability Clin. Biochem. Rev. 26 97-122
41. Seibel M J and Woitge H W 1999 Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects J. Clin. Densitom. 2 299-321
42. Garnero P and Delmas P D 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease J. Clin. Endocrinol. Metab. 77 1046-53 (Pubitemid 23301484)
43. Goldstone A P, Howard J K, Lord G M, Ghatei M A, Gardiner J V and Wang Z L 2002 Leptin prevents the fall in plasma osteocalcin during starvation in male mice Biochem. Biophys. Res. Commun. 295 475-81 (Pubitemid 34785859)
44. Foucault P, Foucault M H, Kucharewicz B, Bureau F, Alix M and Drosdowsky M A 1991 Value of the study of total alkaline phosphatases and bone isoenzyme in a population of subjects with osteoporosis Ann. Biol. Clin. 49 477-81
45. Kim S W, Park D J, Park K S, Kim S Y, Cho B Y, Lee H K and Shin C S 2005 Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis Endocr. J. 52 667-74 (Pubitemid 43104669)
46. Herrmann M and Seibel M J 2008 The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review Clin. Chim. Acta. 393 57-75
47. Altintaş A, Saruhan-Direskeneli G, Benbir G, Demir M and Purisa S 2009 The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J. Neurol. Sci. 276 41-4
48. Chaplet M, Detry C, Deroanne C, Fisher L W, Castronovo V and Bellahcéne A Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition Biochem. J. 384 591-8
49. Greenspan S L, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, Kher U and Gertz B 1996 Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy Proc. Assoc. Am. Physicians 108 230-8
50. Allori A C, Sailon A M and Warren S M 2008 Biological basis of bone formation, remodeling, and repair: part I. Biochemical signaling molecules Tissue Eng. Rev. B 14 259-73
51. Bolland M J, Grey A B, Horne A M, Briggs S E, Thomas M G, Ellis-Pegler R B, Callon K E, Gamble G D and Reid I R 2008 Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months J. Bone Miner. Res. 23 1304-8 (Pubitemid 352040185)
52. Reid I R et al 2011 A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years J. Bone Miner. Res. 26 2261-70
53. Guo H, Su J, Wei J, Kong H and Liu C 2009 Biocompatibility and osteogenicity of degradable Ca-deficient hydroxyapatite scaffolds from calcium phosphate cement for bone tissue engineering Acta Biomater. 5 268-78